RxDoctor Payments Data

Daniel Kohane, MD

Interventional Pain Medicine · Babylon, NYNPI 1235399734

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $19,080 of the $26,629 with a category attached, or 71.7%. 60 manufacturers reported payments, led by International Rehabilitative Sciences, Inc at 26.9% of the total. Reporting peaked in 2024 at $9,797 and has fallen 68.9% since, to $3,047 in 2025.

$26,629in general payments, 2019–2025

Across 1,303 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • International Rehabilitative Sciences, Inc$7K
  • Collegium Pharmaceutical, Inc.$2K
  • Boston Scientific$2K
  • Abbott$2K
  • AbbVie$1K
  • Medtronic$952
  • plus $11K from 54 others

What the payments were for

  • Travel & lodging$3261%
  • Food & beverage$19,08072%
  • Education$580%
  • Other$7,16427%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
International Rehabilitative Sciences, Inc1$7,164
Collegium Pharmaceutical, Inc.392$2,299
Boston Scientific126$2,298
Abbott101$1,741
AbbVie(2 entities)59$1,093
Medtronic(2 entities)58$952
Relievant Medsystems, Inc.22$907
Nevro Corp.78$897
Scilex Pharmaceuticals Inc.40$756
Forte Bio-pharma LLC18$727
Biodelivery Sciences International, Inc.75$608
Amgen(2 entities)29$468
Vertex17$457
Saluda Medical Americas, Inc.5$456
Averitas Pharma Inc.23$441
Vertos Medical, Inc.15$404
Si-bone, Inc.8$402
Nalu Medical, Inc.9$366
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC21$330
Pfizer15$309
Azurity Pharmaceuticals, Inc.19$306
Zyla Life Sciences, Inc.22$294
Virtus Pharmaceuticals LLC21$280
Protega Pharmaceutials Inc10$185
Arbor Pharmaceuticals, Inc.10$181
Fidia Pharma USA Inc.10$154
Novartis7$141
IBSA Pharma Inc.7$139
Kowa Pharmaceuticals America, Inc.9$139
Biohaven Pharmaceuticals, Inc.5$126
Redhill Biopharma Inc.6$121
MML US, Inc.2$118
DJO, LLC2$114
Biotronik NRO, Inc.3$101
Biohaven Pharmaceutical Holding Company Ltd.4$96
Lundbeck LLC5$95
Johnson & Johnson4$85
Daiichi Sankyo Inc.5$84
Assertio Therapeutics, Inc.4$61
Bioventus LLC3$61
Axsome Therapeutics, Inc.2$51
GRT US Holding, Inc.2$51
Takeda Pharmaceuticals U.S.A., Inc.3$51
Stimwave Technologies Incorporated1$50
Valinor Pharma, LLC3$47
Curonix LLC1$46
MDD US Operations, LLC2$46
Sentynl Therapeutics, Inc.3$41
AstraZeneca2$40
Almatica Pharma LLC2$38
Inspire Medical Systems, Inc.2$37
USWM, LLC2$27
Ferring Pharmaceuticals Inc.1$25
Zimmer Biomet1$24
Baudax Bio Inc.1$19
Stryker1$18
Shionogi Inc1$17
Tonix Medicines, Inc.1$16
Sanofi-aventis U.S. LLC1$15
Acelrx Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,629 in reported general payments places this provider in the 85th percentile of 132 interventional pain medicine providers in New York.

See all interventional pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$412,982
Medicare patients
380
Services billed
6,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen453$39,621
Xtampza ErOxycodone Myristate47$31,806
ProlateOxycodone Hcl/Acetaminophen19$13,796
BelbucaBuprenorphine Hcl16$11,748
Diclofenac Sodium60$7,085
Lidocaine56$6,591
Hysingla ErHydrocodone Bitartrate15$5,747
MovantikNaloxegol Oxalate11$5,209
Pregabalin116$3,516
Fentanyl18$3,236
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen146$2,967
Gabapentin220$2,229
Oxycodone Hcl81$1,175
Acetaminophen-CodeineAcetaminophen With Codeine54$1,003
Morphine Sulfate ErMorphine Sulfate40$848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$2,299$43,55463 claims
Forte Bio-pharma LLCProlate$727$13,79619 claims
Redhill Biopharma Inc.Movantik$121$5,20911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 132 interventional pain medicine providers in New York.

Other interventional pain medicine in Babylon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →